Stockreport

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers [Yahoo! Finance]

Context Therapeutics Inc.  (CNTX) 
PDF “Our IND submission for CTIM-76 is a significant milestone for Context,” said Martin Lehr, CEO of Context. “In 2021, we set an aggressive timeline to advance CTIM-76 in [Read more]